Comment on: Benchmarking tocilizumab use for giant cell arteritis

Janagan, Shalini; Guly, Catherine; Skeoch, Sarah; Robson, Joanna C

Abstract

It is with great interest we read the editorial on tocilizumab (TCZ) use in giant cell arteritis (GCA) published on 9th May, 2022 by Conway et al [1]. We write to share some of our data to add weight to the views expressed, particularly in relation to use of TCZ beyond one year
in refractory cases with visual involvement.

• Journal Article Type: Article
• Acceptance Date: Aug 12, 2022
• Online Publication Date: Aug 23, 2022
• Publication Date: Sep 16, 2022
• Deposit Date: Sep 30, 2022
• Publicly Available Date: Sep 30, 2022
• Journal: Rheumatology Advances in Practice
• Print ISSN: 2514-1775
• Publisher: Oxford University Press
• Peer Reviewed: Not Peer Reviewed
• Volume: 6
• Issue: 3
• Article Number: rkac069
• DOI: https://doi.org/10.1093/rap/rkac069
• Keywords: Rheumatology, tocilizumab, giant cell arteritis, arteritis
• Public URL: https://uwe-repository.worktribe.com/output/9943949
• Publisher URL: https://academic.oup.com/rheumap/article/6/3/rkac069/6673922?login=true
• Related Public URLs: Companion paper: Benchmarking tocilizumab use for giant cell arteritis, Conway et al, Rheumatology Advances in Practice, Volume 6, Issue 2, 2022, rkac037, https://doi.org/10.1093/rap/rkac037